Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Memantine hydrochloride
Drug ID BADD_D01379
Description Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease [A1639]. Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease [T556]. In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 [F4366]. In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 [L5953, F4366].
Indications and Usage For the treatment of moderate to severe dementia of the Alzheimer's type.
Marketing Status Prescription; Discontinued
ATC Code N06DX01
DrugBank ID DB01043
KEGG ID D04905
MeSH ID D008559
PubChem ID 181458
TTD Drug ID D01JEU
NDC Product Code 0456-3408; 63629-7154; 71335-1899; 70436-057; 59651-406; 68382-548; 63818-0004; 51407-054; 68180-249; 10370-348; 47335-321; 43353-170; 16714-961; 0832-1112; 65862-652; 70771-1120; 0456-3414; 0527-1222; 0456-3429; 43353-165; 52605-072; 70436-056; 72606-514; 63190-0160; 59651-408; 72578-003; 71335-1798; 70771-1323; 46708-856; 72578-004; 65162-782; 63629-2512; 68180-248; 47335-033; 70436-054; 47335-034; 47335-031; 46708-451; 70771-1322; 17373-1346; 50090-4877; 50370-0011; 63629-1985; 0527-1943; 51407-055; 55289-937; 63629-2143; 59651-404; 45562-1122; 16714-960; 63629-5291; 46016-4111; 63629-2142; 63629-2514; 65162-785; 51407-056; 43975-264; 47335-322; 68788-7165; 59651-405; 50090-4434; 55154-2667; 63629-1984; 63629-7397; 0456-3407; 65162-784; 65862-653; 0456-3421; 63629-2223; 17381-260; 63190-0180; 68382-546; 71335-2013; 51407-284; 72606-515; 70771-1321; 13668-573; 49711-1515; 0904-6737; 64380-774; 65977-0055; 72189-294; 60505-6211; 64380-745; 68382-547; 55111-860; 63629-1956; 29300-171; 51407-057; 63629-2511; 50090-4203; 70436-055; 71335-1863; 10370-349; 63190-0790; 0904-6736; 59651-407; 16714-962; 0456-3200; 0615-8264; 51407-285; 50090-5926; 71610-011; 77382-0090; 0591-3900; 76072-1004; 62332-075; 77382-0070; 52605-071; 0591-3870; 63629-2513; 59285-027; 71335-0346; 60505-6208; 0456-3210; 63629-2222; 55154-2666; 63629-1957; 63629-1982; 0591-3875; 70771-1119; 77382-0080; 27241-071; 63629-1983; 71335-1732; 46016-4112; 10370-347; 43975-242; 65162-783; 68180-246; 60505-6162; 14335-160; 0904-6734; 16714-959; 27241-070; 66651-909; 68180-229; 65015-674; 68180-230; 10370-346; 46708-452; 33342-298; 68382-549; 0456-3422; 0527-1221; 17337-0025; 0456-3206; 0456-3211; 29300-172; 0456-3205; 43975-243; 62756-912; 70518-3338; 71335-1908; 71335-1603; 62332-076; 33342-297; 53747-025; 0832-1113; 0456-3428; 60505-6209; 60505-6210; 68788-7730; 47335-032; 0456-3415; 33342-066; 43975-266; 50090-5832; 70771-1324; 68180-247; 0904-6735
Synonyms Memantine | Memantin | 1,3-Dimethyl-5-aminoadamantane | 1-Amino-3,5-dimethyladamantane | Namenda | Ebixa | Memantine Hydrochloride | Axura | D-145 | D 145 | D145
Chemical Information
Molecular Formula C12H22ClN
CAS Registry Number 41100-52-1
SMILES CC12CC3CC(C1)(CC(C3)(C2)N)C.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Encephalopathy17.13.02.001--
Extrapyramidal disorder17.01.02.007--
Eye pain06.08.03.002--
Eyelid ptosis06.05.01.002; 17.17.02.004--Not Available
Fall12.01.08.002--
Fatigue08.01.01.002--
Fracture15.08.02.001; 12.04.02.001--
Gait disturbance17.02.05.016; 08.01.02.002--
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Generalised tonic-clonic seizure17.12.01.002--Not Available
Glaucoma06.03.01.002--
Haematuria24.07.01.047; 20.02.01.006--
Haemoptysis24.07.01.006; 22.02.03.004; 02.01.02.006--Not Available
Haemorrhage intracranial17.08.01.008; 24.07.04.003--
Hallucination19.10.02.002--
Hallucination, auditory19.10.02.003--Not Available
Hallucination, visual19.10.02.004--Not Available
Headache17.14.01.001--
Hemiplegia17.01.04.002--Not Available
Hepatic failure09.01.03.002--
Hepatitis09.01.07.004--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperkinesia17.01.02.008--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hypoaesthesia17.02.06.023--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages